Qual é o preço para TMS Co., Ltd. (4891)

O preço para TMS Co., Ltd. (4891) é $0.73072946

Qual é a capitalização de mercado para TMS Co., Ltd. (4891)

A capitalização de mercado para TMS Co., Ltd. (4891) é $33.30M

Receita de TMS Co., Ltd. (4891)

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

Ano	Receita	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Receita

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Receita	Diferença de Receita	País
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Moderna, Inc. MRNA.US	$2.23B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Receita

Diferença de Receita

País